Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Basilea Pharmaceutica AG
BSLNBasilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland. Address: Hegenheimermattweg 167b, Allschwil, Switzerland, 4123
Analytics
Preço Alvo de Wall Street
72.46 CHFRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave BSLN
Análise de Dividendos BSLN
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos BSLN
Avaliação de ações BSLN
Relatório BSLN
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |